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Epidemiology
Ischemic heart disease (IHD) is a leading global cause of
premature morbidity and death.1,2 In many countries, the
increase in longevity and improvements in IHD mortality
have plateaued.1,2 Recent consensus IHD guidelines
reflect the diverse spectrum and etiopathogenesis of
patients with chronic coronary syndromes.3 These
include a continuum of coronary atherosclerosis and
disorders of coronary vasomotion, including microvascu-
lar angina and vasospastic angina. Ischemia with no
obstructive coronary artery disease (INOCA) is increas-
ingly recognized and may be caused by transient and/or
sustained impairments in supply-demand of myocardial
perfusion.4-6 Coronary vascular dysfunction may be
structural and/or functional and involve the coronary
artery and/or its microcirculation.6,7 Epicardial coronary
heart disease (CHD) occurs more often in men,8 whereas
functional disorders (microvascular angina and vasospas-
tic angina) are more common in women.9
Diagnosis using anatomical imaging of coronary artery
disease
Following recent randomized trials,8,10-13 diagnostic
imaging using computed tomography coronary angiogra-
phy (CTCA) is recommended as a first-line test for the
assessment of stable chest pain in patients with no prior
history of coronary artery disease (CAD).14-17 The
Scottish Computed Tomography of the Heart (SCOT-
HEART) trial reported that, among patients referred to a
cardiology chest pain clinic with suspected stable angina,
CTCA added to standard care clarified the diagnosis of
CHD and altered subsequent management.8 At 5 years,
CTCA-guided management added to standard care
reduced the rate of death from CHD or nonfatal
myocardial infarction (MI).18 On the other hand,
compared with standard care, anginal symptoms and
quality life at 6 weeks and 6 months were worse in the
CTCA-guided group.19 Several factors may be relevant.
One explanation could be that, in the CTCA group, in
patients who had microvascular angina and/or vasospas-
tic angina, exclusion of angina due to CHD resulted in
discontinuation of angina therapy by protocol which in
turn led to a deterioration in anginal symptoms and
quality of life. This theme is reflected by our observations
in clinical practice relating to patients with persistent,
unexplained anginal symptoms following CTCA-guided
management. Given that only 1 in 5 patients with recent
onset angina has obstructive CAD, this knowledge gap is
relevant. None of the landmark CTCA trials involved
systematic evaluation of non–flow-limiting CAD and
coronary vasomotion8,10-13,19; hence, the prevalence of
coronary vascular dysfunction in the majority of patients
with angina (or ischemic symptoms) and no obstructive
CAD (INOCA) is unknown.Stratified medicine: evidence of endotypes linked to
treatment strategies
The Coronary Microvascular Angina (CorMicA) trial9
providednew insights into the prevalenceofmicrovascular
angina and vasospastic angina in patients selected for
invasive coronary angiography. The CorMicA investigators
prospectively enrolled 391 patients referred for clinically
indicated coronary angiography in a regional center during
a 12-month period. Almost half of this population (n = 185;
47%) had no obstructive CAD. One hundred and fifty-one
subjects entered the randomized trial, and those who had
obstructive CAD (n = 206; 53%) and were therefore
ineligible for randomization entered a registry. CorMicA
involved a 1:1 randomized, blinded, sham-controlled,
parallel-group, clinical trial of stratified medicine versus
standard angiography-guided management. Stratified med-
icine involved adjunctive tests of coronary vascular
function to identify disease endotypes with linked medical
therapy. Compared to standard care, the stratified inter-
vention changed the initial diagnosis based on coronary
angiography in half of the participants in the intervention
group and was associated with directionally consistent
improvements in angina, quality of life, and treatment
satisfaction at 6 months. CorMicA was positioned down-
stream in the care pathway in patients selected for invasive
management. Whether or not endotypes, such as micro-
vascular angina and/or vasospastic angina, might be
common and clinically relevant in a population of patients
presenting with stable angina in the Chest Pain Clinic
setting is unknown. The Chest Pain Clinic represents the
point-of-care linking referrals from primary care with
cardiology in secondary care.
Rationale
Several studies have addressed the prevalence of
microvascular angina and vasospastic angina.9,20,21 How-
ever, the participants in these studies had been referred
and selected for invasive coronary angiography which
takes place downstream in the care pathway. The
prevalence data from these studies may not accurately
reflect the true prevalence of vasomotion disorders. In a
comparatively unselected population of all-comers with
chest symptoms and a lower burden of cardiovascular risk
factors, vasomotion disorders may, potentially, be much
more common than obstructive CAD. In the United
Kingdom, anatomical imaging using CTCA is recommend-
ed as the first-line test for the evaluation of recent-onset
chest pain suspected to be due to CHD.15,16 The Chest Pain
Clinic setting provides an ideal opportunity to assess for the
prevalence of these conditions in a relatively unselected
population, upstream in the care pathway.
Stratified medicine is the identification of key sub-
groups of patients (endotypes) within a heterogeneous
population, these endotypes being distinguishable by
distinct mechanisms of disease and/or responses to
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stratified medicine to benefit patients with angina. The
strategy is now supported by a Class IIA practice
guideline recommendation from the European Society
of Cardiology.17 In CorCTCA, we now propose a
randomized controlled trial to assess whether stratified
medicine is informative and clinically useful in patients
with angina and no obstructive CAD as determined by
CTCA.
Study design and methods
Aim
Our first aim is to assess the prevalence of disease
endotypes in patients with angina and no obstructive
CAD classified by CTCA. Disease endotypes will be
prospectively assessed using an interventional diagnostic
procedure (IDP) including tests of coronary vascular
function during invasive angiography. Our second aim is
to assess the effect of a novel clinical strategy, stratified
medicine guided by the IDP, on diagnosis, treatment, and
well-being. The participants will be randomized before
the IDP to prevent any bias by knowing the treatment
group allocation. The participants will be randomly
allocated into 2 groups: the intervention group (IDP
disclosed, stratified medicine) or the control group (IDP
not disclosed/sham, standard angiography-guided
management).
Hypothesis
In patients with angina in whom obstructive CAD has
been excluded by CTCA, microvascular angina and
vasospastic angina are prevalent. A systematic assessment
of coronary vascular function using invasive coronary
angiography and adjunctive tests of coronary vascular
function will reclassify the diagnosis leading to changes in
treatment and improvements in well-being as compared
to decisions based on CTCA alone. We hypothesize that
clarification of the diagnosis to rule in or rule out disease
endotypes, increasing the certainty of the diagnosis, will
help clinicians make informed therapy decisions. Finally,
we hypothesize that stratified medicine will improve
patient well-being and health care resource utilization.
Objectives
Our research includes 2 primary objectives. The first is
to undertake a diagnostic study, and the second is to
undertake a nested, randomized, controlled, trial in
participants enrolled into the diagnostic study.
Primary objective of the diagnostic study. The
primary objective is to prospectively determine the
prevalence of coronary endotypes in an INOCA popula-
tion as classified by a CTCA. The primary outcome of the
diagnostic study reflects the reclassification of the initial
diagnosis using diagnostic tests of coronary vascular
function. The primary outcome is determined by thereclassification of the following diagnostic groups
(endotypes):
1. Angina due to obstructive CAD (fractional flow
reserve [FFR] ≤0.80);
2. Microvascular angina (coronary flow reserve
[CFR] b2.0 and/or index of microvascular resis-
tance [IMR] N25);
3. Microvascular angina due to spasm (acetylcholine
testing);
4. Vasospastic angina due to coronary spasm
(acetylcholine testing);
5. Noncoronary etiology (normal coronary function).
The reclassification decision (yes/no) will be based on
the results of the IDP versus the diagnosis based on CTCA.
The primary analysis is the between-group comparison of
the reclassification rate using logistic regression, adjusted
for baseline factors associated with the likelihood of
reclassification of the initial diagnosis.
Primary objective of the trial. The primary objective
of the clinical trial is to determine whether stratified
medicine, including disclosure of the coronary function
findings with linked changes in management, leads to
patient benefits. The primary outcome is the within-
subject change at 6 months from baseline for the
domains of the Seattle Angina Questionnaire (SAQ).
Secondary objectives. The secondary objectives will
gather information on health status, physical activity, and
health and economic outcomes.
1. Compare health status using the SAQ, the EuroQol
5-domain health-related quality of life questionnaire,
the Illness Perception Questionnaire, the Patient
Health Questionnaire-4 for anxiety/depression, and
the Treatment Satisfaction Questionnaire for Medi-
cation between the intervention and control groups
at baseline and during follow-up (6, 12, and
24 months or close-out);
2. Compare functional status (Duke Activity Status
Index) and physical activity levels (International
Physical Activity Questionnaire–Short Form) be-
tween the intervention and control groups at
baseline and during follow-up;
3. Compare longer-term health outcomes and resource
utilization including episodes of care and prescrip-
tions between the intervention and control groups
using electronic record linkage;
Tertiary (scientific) outcomes.
1. Measure circulating biomarkers of cardiovascular
function and inflammation;
2. Investigate pathophysiology including the relation-
ships between (1) coronary calcium score, (2) shear
stress, and parameters of coronary vascular function;
Figure 1
Recruitment sites for CorCTCA. Three recruiting hospitals with a catchment area which covers West and Central Scotland (labeled in orange).
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coronary vascular function.
Study design
CorCTCA includes a prospective, diagnostic study and
nested, 1:1 randomized, sham-controlled, parallel-group,
blinded clinical trial.
Setting
Participants will be screened and enrolled at the point
of care for CTCA at 3 or more hospitals in West and
Central Scotland (population ~2.5 million) (Figure 1).
Screening is initially performed by review of the
electronic radiology referrals for CTCA. The subjects
should have anginal symptoms and be referred by their
attending cardiologist for clinically indicated CTCA in line
with the contemporary practice guidelines.14-17
The sites include a regional cardiothoracic center, a
large urban hospital, and a district general hospital. The
geographies include socially diverse populations from
urban and rural communities.Eligibility criteria. To mitigate the possibility of bias
through knowledge of the CTCA findings, the decision to
enroll patients will be made before the CTCA (Figure 2).
Patients referred for CTCA will be invited to give informed
consent and complete the Rose Angina23 and Seattle
Angina Questionnaires.24 The participants' responses
disclosed in these questionnaires will then be assessed
against the eligibility criteria to confirm a history of anginal
symptoms. Participants who report symptoms of angina
and fulfill the eligibility criteria will then be invited to
complete the other health questionnaires before CTCA. By
completing the questionnaires before CTCA, the partici-
pants will be unaware of the imaging results which
therefore cannot influence the patients' responses.
The inclusion criteria are:
1. Age ≥ 18 years.
2. Symptoms of angina or angina-equivalent informed
by the Rose Angina questionnaire.
3. Intermediate or no obstructive coronary disease,
that is, no coronary stenosis N70% in an artery
N2.5 mm, as revealed by CTCA.
Figure 2
Schematic study design: flow diagram. ACh, acetylcholine.
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1. Noncoronary etiology of angina, for example,
anemia, aortic stenosis, and hypertrophic obstruc-
tive cardiomyopathy.
2. Obstructive coronary disease evident in an artery
(diameter N2.5 mm), that is, N50%-70% circumfer-
ential plaque extending for ≥2 coronary segments
or a stenosis N70% as revealed by CTCA.
3. Lack of informed consent.
Exclusion for the randomized study only:
1. Flow-limiting coronary disease defined by
FFR ≤ 0.80 in an artery with a diameter of more
than 2.5 mm.
CTCA will be performed during usual care and acquired
according to a standard protocol. Where preliminary
noncontrast scans are acquired, CT coronary calcium
score will be estimated according to local practice. Oral
and/or intravenous β-blocker therapy (if required for heart
rate control) and sublingual glyceryl trinitrate (GTN)will be
given immediately prior to CTCA in line with local
standards of care. The CTCA should be of sufficient
diagnostic quality to substantiate a conclusive radiology
report whereby disease severity in an epicardial coronaryartery with a diameterN 2.5 mm is classified by the
reporting clinician as absent or present and, if present,
whether the disease is obstructive, that is, N70% severity;
potentially obstructive, N50%-70% circumferential with
plaque extending for≥2 coronary segments; intermediate,
N50%-70%plaquebut not circumferential plaque extending
for severity; or nonobstructive CAD (≤50%). This classifi-
cation aligns with contemporary trials.8,10-13,18 Overall
disease severity will be categorized using the CAD-RADS
reporting system for stable chest pain.25
Participants without obstructive CAD on CTCA will
continue in the study. They will be invited to attend on a
different date for elective coronary angiography with
adjunctive tests of coronary function. These procedures
will be performed in a single reference center (Golden
Jubilee National Hospital). During the angiogram, partici-
pants either with obstructive CAD or who are eligible but
for other reasons, for example, logistical, are not random-
ized will continue in a follow-up registry (Figure 2). The
Research Ethics Committee and Research and Develop-
ment Management Office have approved the protocol.
Randomization and implementation
The treatment plan will be serially recorded by the
attending cardiologist before and after coronary angiog-
raphy but before randomization in the catheter
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reevaluated using invasive coronary angiography and
guidewire-based FFR in any major coronary artery with
CAD N50% of the reference vessel diameter. Participants
who have flow-limiting CAD will be considered for
revascularization by percutaneous coronary intervention
or coronary artery bypass graft surgery, as appropriate.
The participants with no obstructive CAD (FFR N0.80)
will undergo testing of coronary function using an IDP.
The participants will be randomly assigned 1:1 to the
intervention (stratified medicine according to IDP results)
or blinded control (IDP performed but results not
disclosed [sham procedure]; standard-care medical ther-
apy according to physician preference). The results will
be disclosed to the attending cardiologist in the
intervention group and not disclosed in the control
group. In the intervention group, the cardiologist can
reappraise the diagnosis based on coronary angiography
and can change the diagnosis with linked therapy
decisions. In the control group, management will be
guided by coronary angiography and the other available
medical information but not the IDP results. Guideline-
directed medical management will be implemented.17
The attending clinicians will be provided with a
standardized management document (Table I) that is
specific to the final diagnosis (endotype). The same
approach will be implemented for participants in both
groups. The management in the intervention group
reflects stratified medicine with treatment linked to the
endotype (intervention group, IDP disclosed). Manage-
ment in the control group reflects angiography-guided
medical management (IDP not disclosed).
Catheter laboratory staff will use a Web-based random-
ization tool to immediately randomize the patient after
the index coronary angiography revealed no obstructive
CAD (Robertson Centre for Biostatistics, University of
Glasgow). The randomization sequence involves block
lengths randomized in blocks of length 4, that is, every 20
allocations consists of 4 blocks, 2 of length 4 and 2 of
length 6, in a random order. Patients will be considered as
being randomized as soon as the allocation is assigned on
the Web-based portal.
Blinding and adherence
Patients in the control arm will undergo the IDP in the
same way as the participants in the intervention group
except that the results will not be disclosed to the treating
cardiologist in the control group. Blinding will be
implemented by obscuring the hemodynamic monitor
from the clinicians, nurses, and participants such that it
will be impossible for them to observe the IDP results.
Complete blinding will be ensured through the assistance
of a second cardiologist (N. S.) who supervised the
coronary function and vasoreactivity testing protocol.
The attending cardiologist will be invited to leave the
catheter laboratory for the duration of the diagnosticprocedure. For this reason, it is not possible to blind the
cardiologist to the randomized group allocation. The
cardiologist and the participant will remain blinded to the
diagnostic findings in the control group. Pharmacological
tests will be performed in an identical fashion in both
groups. Adherence to monitoring and blinding will be
prospectively recorded by the research staff. The
outcome assessors and statisticians will be blinded to
treatment group allocation.
Coronary function testing (IDP)
The stratified medicine protocol9 is supported by
contemporary practice guidelines.17 On practical
grounds, the IDP will be performed in a single major
coronary artery to curtail the duration of the procedure.
The left anterior descending coronary artery will usually
be the target vessel because it supplies the greatest
amount of ventricular mass. The decision will be at the
discretion of the interventional cardiologist. If the IDP
test results are normal and clinical suspicion remains
high, then additional arteries may be assessed, in line with
clinical judgement.
The IDP involves a coronary thermodilution technique.
A pressure- and temperature-sensitive diagnostic coro-
nary guidewire will be advanced into a major coronary
artery (typically into the left anterior descending coro-
nary artery) for assessment of CFR (abnormal b2.0), IMR
(abnormal N25), and FFR (abnormal ≤0.80) during
intravenous infusion of adenosine (140 μg/kg/min).
Incremental concentrations of acetylcholine (10−6, 10−5,
and 10−4 mol/L) will then be sequentially infused during 2-
minute periods, followed by vasospasm provocation
testing (acetylcholine bolus, 100 μg for left coronary artery
or 50 μg right) and finally 300 μg of glyceryl trinitrate. An
angiogram will be acquired at the end of each infusion
period.
Definitions of endotypes
The IDP will be used by the attending cardiologist to
assess for coronary endotypes according to diagnostic
criteria defined in practice guidelines.17,26,27 Considering
the randomized trial, in the intervention arm, the IDP will
be used to stratify patients into subgroups (endotypes:
microvascular angina, vasospastic angina, both, none, or
flow-limiting CAD [an exclusion criterion]). The diagnosis
of a clinical endotype will be linked to guideline-based
management.17 A diagnosis of vasospastic angina requires
that 3 conditions be satisfied during acetylcholine testing:
(1) clinically significant epicardial vasoconstriction
(≥90%), (2) reproduction of the usual chest pain and, (3)
ischemic electrocardiographic (ECG) changes.27 Microvas-
cular angina is defined according to standardized Coronary
Vasomotion Disorders International Study Group diagnos-
tic criteria26: symptoms of myocardial ischemia, unob-
structed coronary arteries, and evidence of coronary
microvascular dysfunction (any of abnormal IMR, CFR, or
Table I. Endotypes: definitions and guidance therapy for attending cardiologists
Diagnostic group/endotype Outcome definitions Linked therapy
Microvascular
angina
Increased
microvascular
resistance
IMR N25
IMR is a quantitative
method for specifically
assessing microvascular
function independent
resting hemodynamics.
Baseline therapy: consider aspirin, statin,
and ACE-i therapy in all patients.
Sublingual GTN as required.
Antianginal therapy (except microvascular spasm):
1st line
β-Blocker (eg, carvedilol 6.25 mg twice daily,
to be uptitrated)
2nd line
Non-DHP CCBs substituted (eg, verapamil 120 mg
slow release) where β-blockers are not tolerated
or ineffective.
3rd line (add in therapy)
DHP CCB (eg, amlodipine) for those on β-blockers
Nicorandil (5 mg twice daily, to be uptitrated)
Ranolazine (375 mg twice daily, to be uptitrated)
Antianginal therapy (microvascular spasm only):
treat like vasospastic angina (see below)
Refer for cardiac rehabilitation
Reduced coronary
vasorelaxation
CFR b2
This reflects the inability to
increase coronary flow
above 2× the resting flow.
Reduced
microvasodilator
capacity
RRR b2
This reflects the vasodilator
capacity of the microcirculation
to change from baseline
to hyperemia
Microvascular
spasm
Angina with typical ischemic ECG
changes and epicardial coronary
constriction b90% reduction in
epicardial coronary artery diameter
during ACh infusion.
This represents increased microvascular
constriction.
Vasospastic
angina
Epicardial
spasm
Epicardial coronary artery spasm
(N90% reduction in coronary diameter)
with symptoms and ST-segment
changes following IC ACh in
comparison with baseline resting
condition following IC GTN
administration in any epicardial
coronary artery segment.
Baseline therapy:
Aspirin and statin should be considered.
PRN sublingual GTN
Antianginal therapy:
1st line
Non-DHP CCB (eg, verapamil 120 mg
slow release, to be uptitrated)
2nd line (add in therapy)
Add nitrate, eg, isosorbide mononitrate 10 mg BD
3rd line
Change nitrate to nicorandil
(5 mg twice daily, to be uptitrated)
Refer for cardiac rehabilitation
Obstructive
epicardial
stenosis
FFR ≤ 0.80
Baseline therapy:
Aspirin and statin should be considered.
Sublingual GTN as required.
Consideration of revascularization, antianginal
therapy as per ESC guidelines.
Refer for cardiac rehabilitation
Noncardiac
chest pain
FFR N0.80
CFR ≥2
RRR ≥2
IMR ≤25
No functional angina/spasm
during ACh infusion
Cessation of antianginal therapy.
Stop antiplatelet and statin unless other
indication present.
Consider noncardiac investigation or referral
where appropriate.
RRR, resistance reserve ratio; ACh, acetylcholine; ACE-I, angiotensin-converting enzyme inhibitor; DHP, dihydropyridine; CCB, calcium channel blocker; IC, intracoronary; ESC,
European Society of Cardiology.
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coronary microvascular spasm requires provocation and
reproduction of anginal symptoms and ischemic ECG shiftsbut no epicardial spasm during acetylcholine testing.26 A
diagnosis of noncardiac chest pain requires no obstructive
epicardial CAD (FFR N0.80) and an absence of evidence of
Table II. Sample size calculations for the diagnostic study
ample size calculation: change in
iagnosis (% of patients)
Power,
%
Group
size, n
isclosed group Usual-care group
0 0.1⁎ 90 94†
0 0.1⁎ 90 45†
0 5 90 114
5 5 90 75
5 10 80 113
0 10 90 92
Approximately 0%-1% reclassification.
Calculation based on Fisher exact test.
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negative acetylcholine testing).
Stratified medicine in the intervention group
After randomization and completion of the diagnostic
intervention, research staff will invite the cardiologist to
consider the new findings and reevaluate the diagnosis
and treatment plan initially made based on coronary
angiography. The attending cardiologist will be provided
with written management guidance enabling a personal-
ized medicine approach linked to the endotype and
informed by practice guidelines.17 Standardized guidance
letters will be provided to the general practitioner and
attending cardiologist with advice on tailoring and
optimizing treatment (including nonpharmacological
and lifestyle measures). Standard care for participants in
the control arm consists of guideline-directed medical
therapy. The attending cardiologist has discretion over
the final treatment decisions in both groups.
Questionnaires and follow-up
The SAQ is a self-administered, disease-specific measure
of angina severity that is valid, reproducible, and sensitive
to change.24 The SAQ quantifies patients' physical
limitations caused by angina, the frequency of and recent
changes in their symptoms, their satisfaction with treat-
ment, and the degree to which they perceive their disease
to affect their quality of life. Each scale is transformed to a
score of 0 to 100, where higher scores indicate better
function (eg, less physical limitation, less angina, and better
quality of life). The summary score (SAQSS) averages the
domains of angina limitation, frequency, and quality of life
to provide an overall metric of angina severity.24 In the
CorMicA trial, the SAQ disclosed differences between the
randomized groups.9
Health status will be serially assessed using validated, self-
administered questionnaires for quality of life using the
EuroQOL (EQ-5D-5L). This is a widely used standardized
instrument for measuring generic health status whereby
higher scores represent better health-related quality of life
(from−0.59 to 1.00 scale).28,29Wewill also record the Brief
Illness Perception Questionnaire,30 screening for depres-
sion and anxiety (Patient Health Questionnaire-4),31 and
the Treatment Satisfaction Questionnaire for Medication.32
At 6 and 12 months, patients' anginal symptoms will be
reassessed using the same questionnaires.
Sample size calculation and statistical analysis
for the diagnostic study. The primary analysis will be
the between-group comparison of the reclassification
rate using logistic regression, adjusted for baseline
characteristics associated with the likelihood of reclassi-
fication of the initial diagnosis. Prespecified baseline
characteristics are anticipated to include sex and smoking
status. If this is not possible because of small numbers,
logistic regression with fewer adjustment variables or
Fisher exact test will be used as appropriate. A samplesize of 115 per group will have 80% power to detect a
between-group difference of 15%, or 90% power to
detect a difference of 20%, in the proportion of patients
whose diagnosis is reclassified. To allow for any missing
data, 250 patients will be randomized (Table II). If the
coronary function test results are disclosed in the usual-
care group (operator preference; protocol deviation), the
plan before disclosure will be recorded.
Sample size calculation for the randomized
controlled trial. If SAQ scores at 6 months can be
obtained from 180 patients (72%), the trial will have 80%
power to detect a mean between-group difference in
within-subject change in SAQ scores of 0.42 SD unit. This
is a small difference, but we anticipate that not all patients
will have their therapy changed following disclosure of
the IDP result. Using the coronary function data for the
control (nondisclosure) group, we will carry out focused
analyses of the subgroup of patients whose therapy might
have been altered based on abnormal results. For
example, if therapy would be altered in 50% of patients,
the study will have 80% power to detect a difference in
SAQ score of 0.60 SD unit for these patients; if therapy is
altered in 30% of patients, there will be 80% power to
detect a between-group difference of 0.74 SD unit. We
anticipate loss to follow-up in ≤15% of the participants.
The sample size is suggested to be sufficiently large to
limit imprecision and be clinically meaningful.
Statistical analysis of the randomized controlled trial
Continuous outcomes at 6 months will be compared
between study groups using linear regression adjusting
for stratification variables used in the randomization (site,
sex, and CAD on CT scan) and baseline level of the
outcome where applicable. Where residuals are clearly
not normally distributed, standard transformations will be
applied to the outcome prior to analysis to achieve
approximate normal distribution of the residuals. In
addition, changes from baseline at all follow-up measure-
ments will be analyzed over time using linear mixed-
effects regression models. Time-to-event outcomes willS
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proportional hazards regression adjusting for stratifica-
tion variables used in the randomization provided the
proportional hazards assumption is met. Otherwise, log-
rank tests will be used.
Follow-up procedures
Follow-up assessments for adverse events will be
performed by the clinical research staff by telephone
or in person (eg, outpatient clinic review), as appropri-
ate. Medical records will also be checked. Follow-up
contact will occur at 6 monthly intervals until the last
patient has achieved a minimum of 6 months of follow-
up. Follow-up in the longer term (ie, ≥3 years) will be
supported by electronic record linkage with central
government health records. The active phase of the
project will be completed within 30 months. Follow-up
procedures will be the same for patients in both groups.
The adherence to blinding will be prospectively record-
ed and monitored. The participants’ knowledge of their
treatment group assignment will be checked at
12 months.
Written management guidance for each endotype,
informed by practice guidelines, will be provided to the
cardiologist, GP, and nurse practitioners with advice to
start, stop, and optimize treatment (including nonpharma-
cological/lifestylemeasures) in linewith the final diagnosis.
Trial management and governance. The study will
be conducted according to observational (STROBE),33
GCP,34 and CONSORT35 guidelines. The study will be
coordinated by the Study Management Group that
includes those individuals responsible for the day-to-
day management of the study including the Chief
Investigator, Co-Investigators, Research Nurse, and
others as considered appropriate. The role of this
group will be to facilitate the progress of the study,
ensure that the protocol is adhered to, and take
appropriate action to safeguard participants and the
quality of the study itself.
Clinical events identified as potentially relevant to the
designated secondary health outcomes will be assessed
by a Clinical Event Committee. The Clinical Event
Committee will be independent of both the investigators
and the funder/sponsor and will be blinded regarding
any information relating to the randomization group.
Study monitoring will be conducted by monitors on
behalf of the sponsor (NHS Golden Jubilee National
Hospital). During monitoring assessments, informed
consent forms and source clinical data will be reviewed
as appropriate.
Source of funding
This research was supported by the British Heart
Foundation (BHF) and the Chief Scientist Office of the
Scottish Government.Discussion
Our study will provide new information on the
prevalence and clinical significance of microvascular
angina and vasospastic angina in a comparatively
unselected population of patients with angina and no
obstructive CAD classified by clinically indicated CTCA.
The trial includes multiple centers, all of which partici-
pated in the SCOT-HEART trial.8,11 The study design
includes measures to mitigate against bias. Overall, the
study is intended to have transferable relevance to clinical
practice and guidelines.
A clinical strategy of anatomical imaging of CAD
exploits the high negative predictive value of CTCA and
the benefits of identifying coronary atherosclerosis to
stratify affected patients for preventive medical therapy.
Subjects with obstructive CAD can also be referred for
invasive management. However, this strategy does not
take account of myocardial ischemia which is the
downstream consequence of reduced coronary blood
flow due to either an anatomical or functional problem,
or both. Patients with anginal symptoms and no
obstructive CAD classified by CTCA may have myocardial
ischemia due to either a false-negative test result, that is,
flow-limiting CAD (FFR ≤0.80), or ischemia due to
microvascular angina, vasospastic angina, or both.
Microvascular angina typically causes effort- and stress-
induced angina. Vasospastic angina typically occurs
spontaneously or in response to triggers such as exertion,
emotional stress, or cold weather. Affected patients may
experience spontaneous and recurrent episodes of
angina. Patients with vasospastic angina may have a
true-negative stress test result for myocardial ischemia.
The emergence of diagnostic guidewire-based tests of
coronary vascular function opens the door to assessing
endotypes in clinical practice.9,17 The strategy is now
supported by a Class IIA recommendation from the
European Society of Cardiology.17 Specifically, IMR is
informative for structural microvascular disease, and CFR
is informative for functional vasomotion disorders. IMR
and CFR have prognostic significance, including in
INOCA when flow-limiting CAD is ruled out.36 Further-
more, the diagnostic guidewire test complements ad-
junctive provocation testing with acetylcholine —
together, these physiological parameters may predict
propensity to adverse cardiac events.37 Coronary reac-
tivity testing with acetylcholine is used to assess for
vasospasm. This approach is also supported by a Class IIA
guideline recommendation.17
Most patients with recent-onset angina do not have
obstructive CAD. In SCOT-HEART,8 just 25% of the
participants had obstructive CAD (N70% stenosis in ≥1
major branches or 50% in the left main stem). In
PROMISE,10 only 517 (10.7%) of the 4,996 participants
in the CTCA group had obstructive CAD. Both of these
trials had a pragmatic design, and invasive management
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etiology of the angina in the majority of the participants
in these trials, notably the patients without obstructive
CAD. The CE-MARC 2 trial compared 3 diagnostic
strategies ([1] CMR, [2] myocardial perfusion scintigra-
phy group, and [3] NICE guidelines involving CTCA) in
1,202 patients with angina referred to the Chest Pain
Clinic with a pretest likelihood of CAD of 10% to 90%.38
Invasive coronary angiography was performed within
12 months of randomization in 265 (22%) patients. The
primary outcome of unnecessary angiography (defined
as an FFR N0.8 or quantitative coronary analysis
showing no stenosis ≥70% in 1 view or ≥50% in 2
orthogonal views in all coronary vessels ≥2.5 mm
diameter) occurred in 139 subjects (12%): 7.5% in the
CMR group, 7.1% in the myocardial perfusion scintig-
raphy group, and 28.8% of participants in the NICE
guidelines group.38 The CE-MARC 2 physiology sub-
study highlighted that microvascular angina may be
relevant, but invasive tests were not systematically
performed.39
The ISCHEMIA trial investigators40 observed that some of
the participants enrolled with moderate-severe myocardial
ischemia on stress testing (% LV mass) do not have
obstructive CAD. The Changes in Ischemia and Angina
Over 1 Year Among ISCHEMIA Trial Screen Failures With
no Obstructive CAD on Coronary CT Angiography (CIAO)
ISCHEMIA study will investigate ischemia in these patients
using stress echocardiography (ClinicalTrials.gov Identifier:
NCT02347215).
In FAME-2,41,42 of 1,220 patients with stable CAD, 332
(27%) had non–flow-limiting (FFR N0.80) CAD (registry
group). The distribution of the Canadian Cardiovascular
Society angina classes was similar between the random-
ized and medically managed registry populations (P =
.64), as was the prevalence of silent ischemia (16%; P =
.96). The MACE rate in the registry group was 9% at
2 years, highlighting the prognostic implications of non–
flow-limiting CAD.43
The CorCTCA trial is designed to extend the evidence
from these trials and fill key knowledge gaps. CorCTCA
should clarify the prevalence and clinical significance
of vasomotion disorders in INOCA. Considering the
potential clinical implications, anatomical imaging with
CTCA as a first-line test may lead to missed diagnoses of
microvascular angina and vasospastic angina, and
suboptimal outcomes for patients with these condi-
tions. In SCOT-HEART, CTCA was associated with an
increase in anginal symptoms and reduction in quality
of life.19 These outcomes were most pronounced in the
patients with nonobstructive CAD. There could be
several reasons to explain this finding. Firstly, patient
satisfaction may be greater with a definitive diagnosis
and treatment plan, that is, (1) normal coronaries =
stop treatment and (2) obstructive CAD = percutane-
ous coronary intervention or coronary artery bypassgraft surgery, whereas a result of no obstructive CAD
and no change in treatment may reduce patient
satisfaction. Secondly, a false-negative CTCA result
may have resulted in some patients with flow-limiting
CAD not being referred for invasive management. An
alternative strategy involving functional tests, for
example, FFR-CT or ischemia testing, would reduce
this problem.44 Finally, some patients may have had
microvascular disease, and discontinuation of angina
treatment by protocol may have led to a deterioration
symptoms. In light of practice guideline recommenda-
tions,15-17 the community adoption of anatomical
imaging with CTCA as a first-line test for the assessment
of stable chest pain14-16 increases the relevance of our
research, not least because guideline-directed therapy
is recommended for microvascular angina and vaso-
spastic angina.17
The CorCTCA protocol presents some ethical consider-
ations. First, a coronary angiogramexposes the participants
to ionizing radiation. Second, the angiogram is invasive.
Third, following a “negative” CTCA scan result, the
standard of care is typically for discharge from cardiology
review. These points should be balanced against the
possibility of false-negative CTCA results and the potential
benefits of this research. Quality of life,9,19 anginal
symptoms,9,19 and prognosis9,36,43 remain impaired
whenmanagement is guided by anatomical CTCA. Clinical
audit and prospective studies9 indicate persisting service
user dependency. In theNational Health Service, about one
quarter of patients referred for elective coronary angiog-
raphy have previously had an angiogram,9 and repeated
attendance in primary and secondary care by patients with
INOCA is common, yet potentially avoidable.17 These
patients have an unmet need, andmost are female,8 raising
questions around the optimal diagnostic management of
IHD in women.45 Because CTCA is an anatomical test, the
report may underestimate the true severity of CAD, and
some patients with flow-limiting CAD may not be referred
for revascularization.
We do not propose that invasive testing of coronary
function should be indicated in all patients with angina and a
“negative” CTCA scan result, rather that it may be a helpful
option for patients when persistent symptoms are unex-
plained by noninvasive testing. Our study will provide
informationonwhether noninvasive functional testing should
be a primary test option in line with recent guidelines.17Acknowledgements
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